X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Blue Water Biotech and IQVIA will market Blue Water’s commercial portfolio including, Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for benign prostatic hyperplasia and Zontivity (vorapaxar).
Lead Product(s): Finasteride,Tadalafil
Therapeutic Area: Urology Product Name: Entadfi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Blue Water Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2023
Details:
Under the terms of the agreement, IQVIA will collaborate with Coeptis to prioritize the target indications for the SNAP-CAR program and manage activities designed to enable the filing of an Investigational New Drug (IND) application.
Lead Product(s): SNAP CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Coeptis Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 22, 2022
Details:
UpRi is Mersana’s first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables a high drug-to-antibody ratio and controlled bystander effect.
Lead Product(s): Upifitamab Rilsodotin
Therapeutic Area: Oncology Product Name: XMT-1536
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Mersana Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
KX-826 (pruxelutamide) effectively reduced hospitalization/mortality; in particular, for subjects who completed the medication for more than 7 days and middle-and-high-age COVID-19 patients with high risk factors, the protection rate was 100%.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Kintor Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
RPL554 (ensifentrine) combines bronchodilator and anti-inflammatory properties in one compound and has the potential to be an effective treatment for COPD and other respiratory diseases, including asthma and cystic fibrosis.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Verona Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Rapid and significant increase in plasma pyrophosphate (PPi) levels observed for INZ-701, in all three subjects in lowest dose cohort (0.2 mg/kg), in adult subjects with ABCC6 Deficiency.
Lead Product(s): INZ-701
Therapeutic Area: Genetic Disease Product Name: INZ-701
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Inozyme Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
The collaboration will support TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential and clinical development, regulatory and commercial strategies.
Lead Product(s): ILB
Therapeutic Area: Neurology Product Name: ILB
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Tikomed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
FP-101 is a non-hormonal/non-herbal/non-antidepressant product for the treatment of vasomotor symptoms associated with menopause and hot flashes. This indication represents an unmet medical need in a substantial and motivated market.
Lead Product(s): FP-101
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FP-101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Fervent Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
IQVIA Biotech is positioned to collaborate with ASLAN on development plans for ASLAN003 in inflammatory bowel disease, with clinical trials commencing early next year. Enrollment of the first patient in the ASLAN004 Phase 2b trial is expected in the fourth quarter of 2021.
Lead Product(s): ASLAN004
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ASLAN Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2021
Details:
This collaboration will allow NRx to access IQVIA’s domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization (EUA) of ZYESAMI.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Recipient: NRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
